Humacyte shares are trading lower after the company announced that the FDA will require additional time to complete its review of the BLA for ATEV in the treatment of vascular trauma.
Portfolio Pulse from Benzinga Newsdesk
Humacyte shares are trading lower after the company announced that the FDA will require additional time to complete its review of the BLA for ATEV in the treatment of vascular trauma.
August 09, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Humacyte shares are trading lower due to the FDA requiring additional time to complete its review of the BLA for ATEV in the treatment of vascular trauma.
The delay in FDA review is a negative development for Humacyte as it postpones potential approval and commercialization of ATEV, impacting investor sentiment and causing the stock to trade lower.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100